Eli Lilly Reports Detailed Data from the P-III (SURMOUNT-OSA) Trial of Tirzepatide to Treat Obstructive Sleep Apnea
Shots:
- Study 1 & Study 2 in P-III (SURMOUNT-OSA) trial of tirzepatide vs PBO for moderate-to-severe OSA & obese adults met 1EP & 2EPs in both the efficacy & treatment-regimen estimands at 52wks.; published in the NEJM; US FDA approval is anticipated in H2'24; submission to global authorities expected in upcoming wks.
- Study 1 showed, change in AHI: -27.4 & -25.3 vs -4.8 & -5.3, those with AHI<5 or AHI 5-14 with ESS≤10: 43% & 42.2% vs 14.9% & 15.9%, those with ≥50% AHI reduction: 62.3% & 61.2% vs 19.2% & 19%, body wt. change: -18.1% & -17.7% vs -1.3% & -1.6%
- Study 2 showed, change in AHI: -30.4 & -29.3 vs -6.0 & -5.5, those with AHI<5 or AHI 5-14 with ESS≤10: 51.5% & 50.2% vs 13.6% & 14.3%, those with ≥50% AHI reduction: 74.3% & 72.4% vs 22.9% & 23.3%, body wt. change: -20.1% & -19.6% vs -2.3% in both
Ref: Eli Lilly | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
